For research use only. Not for therapeutic Use.
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity[1][2].
Talquetamab (0.00128-4.0 μg/mL, 48 h) effectively induces multiple myeloma cell lysis and leads to a significant increase in the proportion of activated CD4+ and CD8+ T cells, as well as to a dose-dependent increase in the levels of granzyme B and inflammatory cytokines such as IL-6, IL-8 and TNF-α[1].
Talquetamab (JNJ-64407564) (0.1-50 µg, s.c. or i.v.) has significant antitumor activity in H929 and MM mouse models[2].
| Catalog Number | I042202 |
| CAS Number | 2226212-40-2 |
| Purity | ≥95% |
| Reference | [1]. Christie P M Verkleij, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215. [2]. Kodandaram Pillarisetti, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243. |
